METROPOLIS · Health Care · 2026-08-21

Metropolis Healthcare Ltd

4.4WatchEven +1.2Stage 2 · wk 11In scan: Pullback Hunter · Prop Scan · Breakout WatchMARKET: BULL RISING · 2026-08-21
₹557
+2.99% today
₹11,550 Cr · Mid cap
About this companyHealth Care· Hospitals & Diagnostic Centres
Expand ▾

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.

Visit company website →
P/E (TTM)
58.3
Forward 35.4
Earnings Growth (YoY)
+73.0%
Revenue +23.0%
ROE
+13.4%
Profit margin +11.5%
Dividend Yield
0.37%
P/B 7.3
vs 52W High
-6.6%
₹421.8 lo₹596.5 hi
6.6% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 11
1w13w26w
Week 11 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
10.7%
200 DMA: ₹503.1 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
1.65x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -1.0% vs MA50 +2.7%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #57 of 84 Stage 2 stocks in Health Care by RS.
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
55.6%
20d Δ
-7.4pp
1M return
-2.8%
3M return
+2.0%
Industry Stage-2 % · last 20 days
Ranks #10 of 15 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 23w
S2 34w
S4 18w
S3 16w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 7w → S2 6w → S3 4w → S2 23w → S3 2w → S2 34w → S3 8w → S4 18w → S1 10w → S2 11w → S3 16w → S4 11w → S1 4w → S2 11w current
Total tracked: 167 weeks across 15 stage runs.
1M
-1.9%
3M
+7.3%
6M
+15.0%
YTD
+17.9%
1Y
+5.0%
Scan Membership
Pullback Hunter
Latest: 2026-08-13
Prop Scan
Latest: 2026-08-13
Breakout Watch
Latest: 2026-06-05
60 appearances in last 60 days. First seen: 2026-06-05.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 11 · Vol —x
2026-08-20S2
Wk 11 · Vol —x
2026-08-19S2
Wk 11 · Vol —x
2026-08-18S2
Wk 11 · Vol —x
2026-08-17S2
Wk 11 · Vol —x
2026-08-14S2
Wk 10 · Vol —x
2026-08-13S2
Wk 10 · Vol —x
2026-08-12S2
Wk 10 · Vol —x
2026-08-11S2
Wk 10 · Vol —x
2026-08-10S2
Wk 10 · Vol —x
2026-08-07S2
Wk 9 · Vol —x
2026-08-06S2
Wk 9 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹559.3
200 DMA
₹503.1
52W High
₹596.5
52W Low
₹421.8
5D Low
₹540.8
Resistance levels (recent highs)
20d High
₹596.5
60d High
₹596.5
120d High
₹596.5
250d High
₹596.5
Next resistance
+7.1%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.